Speaker Profile
PhD, CEO, BillionToOne
Biography
Dr. Oguzhan Atay is the Co-Founder and CEO of BillionToOne, a next-generation molecular diagnostics company.
Co-developed by Oguzhan, BillionToOne’s QCT molecular counting technology achieves the physical limit of disease detection, shifting the paradigm of cell-free DNA testing for prenatal and oncology care. The rapidly growing UNITY Screen™ is the only NIPT that can assess fetal risk for common recessive conditions such as cystic fibrosis and hemolytic disease of fetus and newborn along with aneuploidies just from maternal blood.
More recently, BillionToOne used the same groundbreaking QCT technology to commercialize Northstar liquid biopsy assays, for cancer therapy selection & treatment monitoring, with an unprecedented limit of detection and precision. BillionToOne has raised more than $300 million in funding to date.
Previously, Oguzhan received his PhD from Stanford, and he graduated summa cum laude and PBK from Princeton with a Bachelor’s in Molecular Biology and minors in Physics, Computer Science, and Mathematics.
Talk
Next-Generation Liquid Biopsies Using World's First Multiplex Molecular Counter
QCTs enable multiplex counting of molecules, enabling single molecule sensitivity and precision at Poisson physical limit. Here, we show how Northstar Select can detect up to 50% more reportable mutations than other methodologies, and Northstar Response precisely quantifies hypermethylated loci, enabling accurate monitoring even in late stage cancers, where surgical removal is not an option.
Clinical Dx Showcase:
BillionToOne
BillionToOne is a precision diagnostics company with the mission to make molecular diagnostics more powerful, accurate, and accessible for all. Our QCT molecular counting platform enables us to offer unique products from single-gene NIPT to quantitative liquid biopsy for treatment monitoring.
Session Abstract – PMWC 2024 Silicon Valley
The PMWC 2024 Data Applications in Clinical Diagnostics Showcase will provide a 15-minute time slot for selected organizations, including commercial companies, clinical testing labs, and medical research institutions, to present their latest advancements, insights, applications, and technologies to an audience of clinicians, leading investigators, academic institutions, pharma and biotech, investors, and potential clients. We will learn about new technologies and findings that promise expedited, cost-effective, and accurate clinical diagnosis for early disease detection, treatment decisions, and disease prevention.
- Clinical Dx/Oncology (including Liquid Biopsy)
- Clinical Dx/Cardio Vascular
- Clinical Dx/Neurodegenerative
